The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InDianthus Therapeutics (DNTH) has announced an early 'GO' decision for its Phase 3 CAPTIVATE trial targeting Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), significantly ahead of its Q2 2026 guidance. CIDP is a rare autoimmune disorder where the immune system damages the myelin sheath of peripheral nerves, leading to progressive muscle weakness and sensory loss lasting over 8 weeks. The decision was triggered after the clinical program met its response criteria, achieving 20 confirmed responders among fewer than 40 participants. Alongside these milestones, the company released its financial results for the fourth quarter and full fiscal year 2025. This acceleration highlights the potential efficacy of the treatment and may shorten the path to market. Investors view these developments as a significant positive catalyst for the company's long-term growth and clinical pipeline validation.